Antithrombotic/Anticoagulant Drugs: World Market 2012-2022
Report Details
Where are antithrombotic and anticoagulant treatments heading? Visiongain's report shows you potential revenues to 2022, with data, forecasts and discussions.
This study assesses drugs to treat abnormal blood clotting in human beings. Discover sales predictions at world market, therapeutic class, product and national levels to 2022.
How will products - Plavix, Lovenox, Pletal, Fragmin, Asasantin, Arixtra, Aspirin Cardio, Effient, Pradaxa, Brilinta and others - perform? Our report gives you business research and analysis with many sales predictions. See the future of the industry and market.
Also, receive forecasting of submarkets, finding potential sales trends from 2012:
What does the future hold? With its R&D pipelines, the pharma industry has potential for improved treatments and increased revenues from blood-thinning agents. Many commercial opportunities remain.
Worldwide, numbers of heart attacks and strokes will rise this decade. Blood thinners will play important roles in medicine, helping to prevent and treat cardiovascular disorders.
Visiongain's study provides data, analysis and opinion aiming to benefit your research, calculations, meetings and presentations. You will find answers in our work.
Revenue forecasts, market shares, developmental trends, discussions and interviews
In the report you find revenue forecasting, growth rates, market shares, qualitative analyses (including SWOT and STEP), opinions and R&D news. You receive 82 tables and charts and four research interviews.
Advantages of Antithrombotic/Anticoagulant Drugs: World Market 2012-2022 for your work
In particular, this study gives you the following knowledge and benefits:
Gain business research, data and analysis for treatment of blood clotting disorders
Our study is for everybody needing industry and market analyses for blood-thinning drugs. Find data, trends and answers. Avoid missing out - please order our report now.
Where are antithrombotic and anticoagulant treatments heading? Visiongain's report shows you potential revenues to 2022, with data, forecasts and discussions.
This study assesses drugs to treat abnormal blood clotting in human beings. Discover sales predictions at world market, therapeutic class, product and national levels to 2022.
How will products - Plavix, Lovenox, Pletal, Fragmin, Asasantin, Arixtra, Aspirin Cardio, Effient, Pradaxa, Brilinta and others - perform? Our report gives you business research and analysis with many sales predictions. See the future of the industry and market.
Also, receive forecasting of submarkets, finding potential sales trends from 2012:
- Platelet aggregation inhibitors
- Heparins
- Fibrinolytics
- Vitamin K antagonists
- Direct thrombin inhibitors
- Direct factor Xa inhibitors.
What does the future hold? With its R&D pipelines, the pharma industry has potential for improved treatments and increased revenues from blood-thinning agents. Many commercial opportunities remain.
Worldwide, numbers of heart attacks and strokes will rise this decade. Blood thinners will play important roles in medicine, helping to prevent and treat cardiovascular disorders.
Visiongain's study provides data, analysis and opinion aiming to benefit your research, calculations, meetings and presentations. You will find answers in our work.
Revenue forecasts, market shares, developmental trends, discussions and interviews
In the report you find revenue forecasting, growth rates, market shares, qualitative analyses (including SWOT and STEP), opinions and R&D news. You receive 82 tables and charts and four research interviews.
Advantages of Antithrombotic/Anticoagulant Drugs: World Market 2012-2022 for your work
In particular, this study gives you the following knowledge and benefits:
- Find revenue predictions to 2022 for the overall world market and submarkets
- Discover revenue forecasts to 2022 for 14 drugs, assessing commercial potential
- See revenue forecasts to 2022 for leading national markets - US, Japan, Germany, France, UK, Spain, Italy, China and India
- Assess leading companies, discovering activities and outlooks
- Review R&D, seeing pipeline trends
- Investigate competition and opportunities influencing sales results
- Find out what will stimulate and restrain the industry and market
- View opinions from our survey of authorities on the sector.
Gain business research, data and analysis for treatment of blood clotting disorders
Our study is for everybody needing industry and market analyses for blood-thinning drugs. Find data, trends and answers. Avoid missing out - please order our report now.
1. EXECUTIVE SUMMARY
1.1 Antithrombotic/Anticoagulant Drug: World Market Overview
1.2 Aims, Scope and Format of the Report
1.3 Research and Analysis Methods
2. BLOOD CLOTTING: MECHANISM, DISORDERS AND TREATMENTS
2.1 Thrombosis
2.1.1 Venous Thrombosis
2.1.2 Arterial Thrombosis
2.2 Complications of Thrombosis
2.2.1 Pulmonary Embolism
2.2.2 Stroke
2.2.3 Myocardial Infarction
2.2.4 Acute Coronary Syndrome
2.3 Antithrombotic Treatments
2.3.1 Platelet Aggregation Inhibitors
2.3.1.1 Glycoprotein Inhibitors
2.3.1.2 Aspirin
2.3.1.3 Thienopyridines
2.3.2 Heparins
2.3.3 Fibrinolytics
2.3.3.1 Streptokinase and Urokinase
2.3.3.2 Tissue Plasminogen Activator (tPA)
2.3.3.3 Other Thrombolytic Agents
2.3.4 Vitamin K Antagonists
2.3.5 Direct Thrombin Inhibitors
2.3.6 Direct Factor Xa Inhibitors
3. ANTITHROMBOTIC DRUGS: WORLD MARKET 2012-2022
3.1 The Antithrombotic/Anticoagulant Drug Market in 2010
3.2 The Antithrombotic/Anticoagulant Drug Market Forecast 2012-2022
3.3 The Leading Antithrombotic/Anticoagulant Therapeutic Classes
3.3.1 The Leading Therapeutic Classes in 2010
3.3.2 Leading Therapeutic Class Forecast 2012-2022
3.4 Platelet Aggregation Inhibitors
3.4.1 Platelet Aggregation Inhibitors Dominated the Market in 2010
3.4.2 Platelet Aggregation Inhibitors: Market Forecast 2012-2022
3.5 Heparins
3.5.1 The Heparins Market in 2010
3.5.2 Heparins: Market Forecast 2012-2022
3.6 Fibrinolytics
3.6.1 The Fibrinolytics Market in 2010
3.6.2 Fibrinolytics: Market Forecast 2012-2022
3.7 Vitamin K Antagonists
3.7.1 Vitamin K Antagonists Market in 2010
3.7.2 Vitamin K Antagonists Market Forecast 2012-2022
3.8 Direct Thrombin Inhibitors
3.8.1 Direct Thrombin Inhibitors Market in 2010
3.8.2 Direct Thrombin Inhibitors: Market Forecast 2012-2022
3.9 Direct Factor Xa Inhibitors
3.9.1 Direct Factor Xa Inhibitors Market in 2010
3.9.2 Direct Factor Xa Inhibitors: Market Forecast 2012-2022
3.10 Chapter Summary
4. LEADING NATIONAL MARKETS FOR ANTITHROMBOTIC/ANTICOAGULANT DRUGS, 2012-2022
4.1 Leading National Markets in 2010
4.2 Leading National Markets: Forecasts to 2022
4.3 The US Antithrombotic/Anticoagulant Drug Market, 2012-2022
4.4 The Japanese Antithrombotic/Anticoagulant Drug Market, 2012-2022
4.5 Leading European Antithrombotic/Anticoagulant Drug Markets, 2012-2022
4.6 The Chinese Antithrombotic/Anticoagulant Drug Market, 2012-2022
4.7 The Indian Antithrombotic/Anticoagulant Drug Market, 2012-2022
5. LEADING ANTITHROMBOTIC/ANTICOAGULANT DRUGS, 2012-2022
5.1 The Leading Drugs of 2010
5.2 Plavix - Commercial Prospects
5.2.1 Plavix: The Leading Anticoagulant of 2010
5.2.2 Plavix Sales Forecast, 2012-2022
5.2.3 Generic Competition
5.2.4 Branded Competition
5.3 Lovenox
5.3.1 Lovenox Sales Forecast, 2012-2022
5.3.2 Competition for Lovenox
5.4 Pletal
5.4.1 Pletal Sales, 2010
5.4.2 Pletal Sales Forecast, 2012-2022
5.5 Fragmin
5.5.1 Fragmin Sales, 2010
5.5.2 Fragmin Sales Forecast, 2012-2022
5.6 Asasantin
5.6.1 Asasantin Sales, 2010
5.6.2 Asasantin Sales Forecast, 2012-2022
5.7 Arixtra
5.7.1 Arixtra Sales, 2010
5.7.2 Arixtra Sales Forecast, 2012-2022
5.8 Aspirin Cardio
5.8.1 Aspirin Cardio Sales, 2010
5.8.2 Aspirin Cardio Sales Forecast, 2012-2022
5.9 Opalmon
5.9.1 Opalmon Sales, 2010
5.9.2 Opalmon Sales Forecast, 2012-2022
5.10 Angiomax
5.10.1 Angiomax Sales, 2010
5.10.2 Angiomax Sales Forecast, 2012-2022
5.11 Activase
5.11.1 Activase Sales, 2010
5.11.2 Activase Sales Forecast, 2012-2022
5.12 Newly Launched Drugs, 2009-2011
5.12.1 Eli Lilly's Effient
5.12.1.1 Effient Sales Forecast, 2012-2022
5.12.1.2 Competition for Effient
5.12.2 Boehringer Ingelheim's Pradaxa
5.12.2.1 Pradaxa Sales Forecast, 2012-2022
5.12.2.2 Competition for Pradaxa
5.12.3 AstraZeneca's Brilinta
5.12.3.1 Brilinta Sales Forecast, 2012-2022
5.12.3.2 Competition for Brilinta
5.12.4 Johnson & Johnson/Bayer's Xarelto
5.12.4.1 Xarelto Sales Forecast, 2012-2022
5.12.4.2 Competition for Xarelto
5.13 Chapter Summary
6. ANTITHROMBOTIC/ANTICOAGULANT DRUG R&D PIPELINE
6.1 Platelet Aggregation Inhibitors R&D Pipeline, 2011
6.1.1 Portola/Novartis's Elinogrel
6.2 Heparins R&D Pipeline, 2011
6.2.1 Sanofi's Semuloparin
6.3 Fibrinolytics R&D Pipeline, 2011
6.3.1 Lundbeck/Berlex/Bayer's Desmoteplase
6.4 Direct Thrombin Inhibitors R&D Pipeline, 2011
6.4.1 Merck's Vorapaxar
6.4.2 Eisai's Atopaxar
6.5 Direct Factor Xa Inhibitors R&D Pipeline, 2011
6.5.1 BMS/Pfizer's Apixaban
6.5.2 Portola's Betrixaban
6.5.3 Daiichi Sankyo's Edoxaban
6.6 R&D Pipeline for Other Antithrombotic Drugs, 2011
6.6.1 Endotis/Merck's EP217609
7. SWOT AND STEP ANALYSES
7.1 Principal Market Drivers
7.1.1 Rising Disease Prevalence
7.1.2 Risk Factors: Management Rather Than Cure
7.1.3 Opportunities for Continuous Growth
7.1.3.1 Standing Out from Competitors
7.1.3.2 Cost-Effective Replacement of Warfarin
7.1.3.3 Antidotes in Demand
7.1.3.4 Further Development of Existing Drugs
7.1.3.5 Exploring New Markets
7.1.4 Advances in Technology Will Bring Benefits to the Market
7.2 Principal Market Restraints
7.2.1 Highly Competitive Market
7.2.1.1 Generic Competition
7.2.1.2 Branded Competition
7.2.2 Cost-Reduction Pressure
7.2.3 Stringent Regulations
8. RESEARCH INTERVIEWS
8.1 Interview with Dr Charles E. Mahan (Director of Outcomes Research, New Mexico Heart Institute, Albuquerque, New Mexico)
8.1.1 Unmet Needs
8.1.2 Major Areas of Focus
8.1.3 New Drug Potential
8.1.4 Key Market Drivers
8.1.5 Opportunities for Revenue Growth
8.2 Interview with Dr Maurice Petitou (Head of Preclinical Research and Development, Endotis Pharma)
8.2.1 EP217609: The First Neutralizable Anticoagulant
8.2.2 Drug Targets Worth Exploring
8.2.3 New Drug Potential
8.2.4 Unmet Needs
8.3 Interview with Dr Jonathan L. Halperin (Professor of Medicine, Director of Clinical Cardiology Services, Zena and Michael A. Wiener Cardiovascular Institute, The Mount Sinai Medical Center, New York)
8.3.1 Unmet Needs
8.3.2 New Findings
8.3.3 Warfarin Replacement
8.3.4 Areas Demanding Attention
8.3.5 Key Market Restraints
8.4 Interview with Dr Jeffrey I. Weitz (Professor of Medicine & Biochemistry, McMaster University, and Executive Director, Thrombosis & Atherosclerosis Research Institute, Ontario)
8.4.1 Unmet Needs
8.4.2 New Oral Anticoagulants
8.4.3 Future Areas of Focus
8.4.4 New Drug Potential
8.4.5 Market Drivers and Restraints
9. CONCLUSIONS
9.1 World Market Overview to 2022
9.2 Leading Drug Classes
9.3 Leading Products
9.4 Leading National Markets
9.5 The Future of the Antithrombotic/Anticoagulant Drug Market
9.5.1 Challenges
9.5.2 Opportunities
1.1 Antithrombotic/Anticoagulant Drug: World Market Overview
1.2 Aims, Scope and Format of the Report
1.3 Research and Analysis Methods
2. BLOOD CLOTTING: MECHANISM, DISORDERS AND TREATMENTS
2.1 Thrombosis
2.1.1 Venous Thrombosis
2.1.2 Arterial Thrombosis
2.2 Complications of Thrombosis
2.2.1 Pulmonary Embolism
2.2.2 Stroke
2.2.3 Myocardial Infarction
2.2.4 Acute Coronary Syndrome
2.3 Antithrombotic Treatments
2.3.1 Platelet Aggregation Inhibitors
2.3.1.1 Glycoprotein Inhibitors
2.3.1.2 Aspirin
2.3.1.3 Thienopyridines
2.3.2 Heparins
2.3.3 Fibrinolytics
2.3.3.1 Streptokinase and Urokinase
2.3.3.2 Tissue Plasminogen Activator (tPA)
2.3.3.3 Other Thrombolytic Agents
2.3.4 Vitamin K Antagonists
2.3.5 Direct Thrombin Inhibitors
2.3.6 Direct Factor Xa Inhibitors
3. ANTITHROMBOTIC DRUGS: WORLD MARKET 2012-2022
3.1 The Antithrombotic/Anticoagulant Drug Market in 2010
3.2 The Antithrombotic/Anticoagulant Drug Market Forecast 2012-2022
3.3 The Leading Antithrombotic/Anticoagulant Therapeutic Classes
3.3.1 The Leading Therapeutic Classes in 2010
3.3.2 Leading Therapeutic Class Forecast 2012-2022
3.4 Platelet Aggregation Inhibitors
3.4.1 Platelet Aggregation Inhibitors Dominated the Market in 2010
3.4.2 Platelet Aggregation Inhibitors: Market Forecast 2012-2022
3.5 Heparins
3.5.1 The Heparins Market in 2010
3.5.2 Heparins: Market Forecast 2012-2022
3.6 Fibrinolytics
3.6.1 The Fibrinolytics Market in 2010
3.6.2 Fibrinolytics: Market Forecast 2012-2022
3.7 Vitamin K Antagonists
3.7.1 Vitamin K Antagonists Market in 2010
3.7.2 Vitamin K Antagonists Market Forecast 2012-2022
3.8 Direct Thrombin Inhibitors
3.8.1 Direct Thrombin Inhibitors Market in 2010
3.8.2 Direct Thrombin Inhibitors: Market Forecast 2012-2022
3.9 Direct Factor Xa Inhibitors
3.9.1 Direct Factor Xa Inhibitors Market in 2010
3.9.2 Direct Factor Xa Inhibitors: Market Forecast 2012-2022
3.10 Chapter Summary
4. LEADING NATIONAL MARKETS FOR ANTITHROMBOTIC/ANTICOAGULANT DRUGS, 2012-2022
4.1 Leading National Markets in 2010
4.2 Leading National Markets: Forecasts to 2022
4.3 The US Antithrombotic/Anticoagulant Drug Market, 2012-2022
4.4 The Japanese Antithrombotic/Anticoagulant Drug Market, 2012-2022
4.5 Leading European Antithrombotic/Anticoagulant Drug Markets, 2012-2022
4.6 The Chinese Antithrombotic/Anticoagulant Drug Market, 2012-2022
4.7 The Indian Antithrombotic/Anticoagulant Drug Market, 2012-2022
5. LEADING ANTITHROMBOTIC/ANTICOAGULANT DRUGS, 2012-2022
5.1 The Leading Drugs of 2010
5.2 Plavix - Commercial Prospects
5.2.1 Plavix: The Leading Anticoagulant of 2010
5.2.2 Plavix Sales Forecast, 2012-2022
5.2.3 Generic Competition
5.2.4 Branded Competition
5.3 Lovenox
5.3.1 Lovenox Sales Forecast, 2012-2022
5.3.2 Competition for Lovenox
5.4 Pletal
5.4.1 Pletal Sales, 2010
5.4.2 Pletal Sales Forecast, 2012-2022
5.5 Fragmin
5.5.1 Fragmin Sales, 2010
5.5.2 Fragmin Sales Forecast, 2012-2022
5.6 Asasantin
5.6.1 Asasantin Sales, 2010
5.6.2 Asasantin Sales Forecast, 2012-2022
5.7 Arixtra
5.7.1 Arixtra Sales, 2010
5.7.2 Arixtra Sales Forecast, 2012-2022
5.8 Aspirin Cardio
5.8.1 Aspirin Cardio Sales, 2010
5.8.2 Aspirin Cardio Sales Forecast, 2012-2022
5.9 Opalmon
5.9.1 Opalmon Sales, 2010
5.9.2 Opalmon Sales Forecast, 2012-2022
5.10 Angiomax
5.10.1 Angiomax Sales, 2010
5.10.2 Angiomax Sales Forecast, 2012-2022
5.11 Activase
5.11.1 Activase Sales, 2010
5.11.2 Activase Sales Forecast, 2012-2022
5.12 Newly Launched Drugs, 2009-2011
5.12.1 Eli Lilly's Effient
5.12.1.1 Effient Sales Forecast, 2012-2022
5.12.1.2 Competition for Effient
5.12.2 Boehringer Ingelheim's Pradaxa
5.12.2.1 Pradaxa Sales Forecast, 2012-2022
5.12.2.2 Competition for Pradaxa
5.12.3 AstraZeneca's Brilinta
5.12.3.1 Brilinta Sales Forecast, 2012-2022
5.12.3.2 Competition for Brilinta
5.12.4 Johnson & Johnson/Bayer's Xarelto
5.12.4.1 Xarelto Sales Forecast, 2012-2022
5.12.4.2 Competition for Xarelto
5.13 Chapter Summary
6. ANTITHROMBOTIC/ANTICOAGULANT DRUG R&D PIPELINE
6.1 Platelet Aggregation Inhibitors R&D Pipeline, 2011
6.1.1 Portola/Novartis's Elinogrel
6.2 Heparins R&D Pipeline, 2011
6.2.1 Sanofi's Semuloparin
6.3 Fibrinolytics R&D Pipeline, 2011
6.3.1 Lundbeck/Berlex/Bayer's Desmoteplase
6.4 Direct Thrombin Inhibitors R&D Pipeline, 2011
6.4.1 Merck's Vorapaxar
6.4.2 Eisai's Atopaxar
6.5 Direct Factor Xa Inhibitors R&D Pipeline, 2011
6.5.1 BMS/Pfizer's Apixaban
6.5.2 Portola's Betrixaban
6.5.3 Daiichi Sankyo's Edoxaban
6.6 R&D Pipeline for Other Antithrombotic Drugs, 2011
6.6.1 Endotis/Merck's EP217609
7. SWOT AND STEP ANALYSES
7.1 Principal Market Drivers
7.1.1 Rising Disease Prevalence
7.1.2 Risk Factors: Management Rather Than Cure
7.1.3 Opportunities for Continuous Growth
7.1.3.1 Standing Out from Competitors
7.1.3.2 Cost-Effective Replacement of Warfarin
7.1.3.3 Antidotes in Demand
7.1.3.4 Further Development of Existing Drugs
7.1.3.5 Exploring New Markets
7.1.4 Advances in Technology Will Bring Benefits to the Market
7.2 Principal Market Restraints
7.2.1 Highly Competitive Market
7.2.1.1 Generic Competition
7.2.1.2 Branded Competition
7.2.2 Cost-Reduction Pressure
7.2.3 Stringent Regulations
8. RESEARCH INTERVIEWS
8.1 Interview with Dr Charles E. Mahan (Director of Outcomes Research, New Mexico Heart Institute, Albuquerque, New Mexico)
8.1.1 Unmet Needs
8.1.2 Major Areas of Focus
8.1.3 New Drug Potential
8.1.4 Key Market Drivers
8.1.5 Opportunities for Revenue Growth
8.2 Interview with Dr Maurice Petitou (Head of Preclinical Research and Development, Endotis Pharma)
8.2.1 EP217609: The First Neutralizable Anticoagulant
8.2.2 Drug Targets Worth Exploring
8.2.3 New Drug Potential
8.2.4 Unmet Needs
8.3 Interview with Dr Jonathan L. Halperin (Professor of Medicine, Director of Clinical Cardiology Services, Zena and Michael A. Wiener Cardiovascular Institute, The Mount Sinai Medical Center, New York)
8.3.1 Unmet Needs
8.3.2 New Findings
8.3.3 Warfarin Replacement
8.3.4 Areas Demanding Attention
8.3.5 Key Market Restraints
8.4 Interview with Dr Jeffrey I. Weitz (Professor of Medicine & Biochemistry, McMaster University, and Executive Director, Thrombosis & Atherosclerosis Research Institute, Ontario)
8.4.1 Unmet Needs
8.4.2 New Oral Anticoagulants
8.4.3 Future Areas of Focus
8.4.4 New Drug Potential
8.4.5 Market Drivers and Restraints
9. CONCLUSIONS
9.1 World Market Overview to 2022
9.2 Leading Drug Classes
9.3 Leading Products
9.4 Leading National Markets
9.5 The Future of the Antithrombotic/Anticoagulant Drug Market
9.5.1 Challenges
9.5.2 Opportunities
LIST OF TABLES
Table 3.1 Antithrombotic/Anticoagulant Drug Market Forecast ($bn), 2010-2016
Table 3.2 Antithrombotic/Anticoagulant Drug Market Forecast ($bn), 2017-2022
Table 3.3 Leading Antithrombotic/Anticoagulant Therapeutic Classes: Sales ($bn) and Market Shares (%), 2010
Table 3.4 Antithrombotic/Anticoagulant Therapeutic Class Forecasts ($bn), 2010-2016
Table 3.5 Antithrombotic/Anticoagulant Therapeutic Class Forecasts ($bn), 2017-2022
Table 3.6 Platelet Aggregation Inhibitors: Market Forecast ($bn), 2010-2022
Table 3.7 Heparins: Market Forecast ($bn), 2010-2022
Table 3.8 Fibrinolytics: Market Forecast ($bn), 2010-2022
Table 3.9 Vitamin K Antagonists: Market Forecast ($bn), 2010-2022
Table 3.10 Direct Thrombin Inhibitors: Market Forecast ($bn), 2010-2022
Table 3.11 Direct Factor Xa Inhibitors: Market Forecast ($bn), 2010-2022
Table 4.1 Antithrombotic/Anticoagulant Drugs: Leading National Markets, 2010
Table 4.2 Leading National Markets: Forecasts ($bn), 2010-2022
Table 4.3 Antithrombotic/Anticoagulant Drug Market Shares (%) by Country, 2012 & 2022
Table 4.4 US Antithrombotic/Anticoagulant Drug Market Forecast ($bn), 2010-2022
Table 4.5 Japanese Antithrombotic/Anticoagulant Drug Market Forecast ($bn), 2010-2022
Table 4.6 Leading European Antithrombotic/Anticoagulant Drug Market Forecasts ($bn), 2010-2022
Table 4.7 Chinese Antithrombotic/Anticoagulant Drug Market Forecast ($bn), 2010-2022
Table 4.8 Indian Antithrombotic/Anticoagulant Drug Market Forecast ($bn), 2010-2022
Table 5.1 Leading Antithrombotic/Anticoagulant Drugs: Sales ($m) and Market Shares (%), 2010
Table 5.2 Leading Antithrombotic/Anticoagulant Drugs: Forecasts ($m), 2010-2022
Table 5.3 Plavix Sales Forecast ($m), 2010-2022
Table 5.4 Lovenox Sales Forecast ($m), 2010-2022
Table 5.5 Pletal Sales Forecast ($m), 2010-2022
Table 5.6 Fragmin Sales Forecast ($m), 2010-2022
Table 5.7 Asasantin Sales Forecast ($m), 2010-2022
Table 5.8 Arixtra Sales Forecast ($m), 2010-2022
Table 5.9 Aspirin Cardio Sales Forecast ($m), 2010-2022
Table 5.10 Opalmon Sales Forecast ($m), 2010-2022
Table 5.11 Angiomax Sales Forecast ($m), 2010-2022
Table 5.12 Activase Sales Forecast ($m), 2010-2022
Table 5.13 Newly Launched Drugs, 2009-2011
Table 5.14 Effient Sales Forecast ($m), 2010-2022
Table 5.15 Pradaxa Sales Forecast ($m), 2011-2022
Table 5.16 Brilinta Sales Forecast ($m), 2011-2022
Table 5.17 Xarelto Sales Forecast ($m), 2011-2022
Table 6.1 Platelet Aggregation Inhibitors: R&D Pipeline, 2011
Table 6.2 Heparin Drugs: R&D Pipeline, 2011
Table 6.3 Fibrinolytics: R&D Pipeline, 2011
Table 6.4 Direct Thrombin Inhibitors: R&D Pipeline, 2011
Table 6.5 Direct Factor Xa Inhibitors: R&D Pipeline, 2011
Table 6.6 R&D Pipeline for Other Antithrombotic Agents, 2011
Table 7.1 SWOT Analysis, 2012-2022
Table 7.2 STEP Analysis, 2012-2022
Table 9.1 World Market Forecast ($bn), 2010-2022
Table 3.1 Antithrombotic/Anticoagulant Drug Market Forecast ($bn), 2010-2016
Table 3.2 Antithrombotic/Anticoagulant Drug Market Forecast ($bn), 2017-2022
Table 3.3 Leading Antithrombotic/Anticoagulant Therapeutic Classes: Sales ($bn) and Market Shares (%), 2010
Table 3.4 Antithrombotic/Anticoagulant Therapeutic Class Forecasts ($bn), 2010-2016
Table 3.5 Antithrombotic/Anticoagulant Therapeutic Class Forecasts ($bn), 2017-2022
Table 3.6 Platelet Aggregation Inhibitors: Market Forecast ($bn), 2010-2022
Table 3.7 Heparins: Market Forecast ($bn), 2010-2022
Table 3.8 Fibrinolytics: Market Forecast ($bn), 2010-2022
Table 3.9 Vitamin K Antagonists: Market Forecast ($bn), 2010-2022
Table 3.10 Direct Thrombin Inhibitors: Market Forecast ($bn), 2010-2022
Table 3.11 Direct Factor Xa Inhibitors: Market Forecast ($bn), 2010-2022
Table 4.1 Antithrombotic/Anticoagulant Drugs: Leading National Markets, 2010
Table 4.2 Leading National Markets: Forecasts ($bn), 2010-2022
Table 4.3 Antithrombotic/Anticoagulant Drug Market Shares (%) by Country, 2012 & 2022
Table 4.4 US Antithrombotic/Anticoagulant Drug Market Forecast ($bn), 2010-2022
Table 4.5 Japanese Antithrombotic/Anticoagulant Drug Market Forecast ($bn), 2010-2022
Table 4.6 Leading European Antithrombotic/Anticoagulant Drug Market Forecasts ($bn), 2010-2022
Table 4.7 Chinese Antithrombotic/Anticoagulant Drug Market Forecast ($bn), 2010-2022
Table 4.8 Indian Antithrombotic/Anticoagulant Drug Market Forecast ($bn), 2010-2022
Table 5.1 Leading Antithrombotic/Anticoagulant Drugs: Sales ($m) and Market Shares (%), 2010
Table 5.2 Leading Antithrombotic/Anticoagulant Drugs: Forecasts ($m), 2010-2022
Table 5.3 Plavix Sales Forecast ($m), 2010-2022
Table 5.4 Lovenox Sales Forecast ($m), 2010-2022
Table 5.5 Pletal Sales Forecast ($m), 2010-2022
Table 5.6 Fragmin Sales Forecast ($m), 2010-2022
Table 5.7 Asasantin Sales Forecast ($m), 2010-2022
Table 5.8 Arixtra Sales Forecast ($m), 2010-2022
Table 5.9 Aspirin Cardio Sales Forecast ($m), 2010-2022
Table 5.10 Opalmon Sales Forecast ($m), 2010-2022
Table 5.11 Angiomax Sales Forecast ($m), 2010-2022
Table 5.12 Activase Sales Forecast ($m), 2010-2022
Table 5.13 Newly Launched Drugs, 2009-2011
Table 5.14 Effient Sales Forecast ($m), 2010-2022
Table 5.15 Pradaxa Sales Forecast ($m), 2011-2022
Table 5.16 Brilinta Sales Forecast ($m), 2011-2022
Table 5.17 Xarelto Sales Forecast ($m), 2011-2022
Table 6.1 Platelet Aggregation Inhibitors: R&D Pipeline, 2011
Table 6.2 Heparin Drugs: R&D Pipeline, 2011
Table 6.3 Fibrinolytics: R&D Pipeline, 2011
Table 6.4 Direct Thrombin Inhibitors: R&D Pipeline, 2011
Table 6.5 Direct Factor Xa Inhibitors: R&D Pipeline, 2011
Table 6.6 R&D Pipeline for Other Antithrombotic Agents, 2011
Table 7.1 SWOT Analysis, 2012-2022
Table 7.2 STEP Analysis, 2012-2022
Table 9.1 World Market Forecast ($bn), 2010-2022
LIST OF FIGURES
Figure 3.1 Antithrombotic/Anticoagulant Drug Market Forecast ($bn), 2010-2022
Figure 3.2 Leading Antithrombotic/Anticoagulant Therapeutic Classes: Market Shares (%), 2010
Figure 3.3 Leading Therapeutic Class Forecast: Market Shares (%), 2012
Figure 3.4 Leading Therapeutic Class Forecast: Market Shares (%), 2022
Figure 3.5 Platelet Aggregation Inhibitors: Market Forecast ($bn), 2010-2022
Figure 3.6 Heparins: Market Forecast ($bn), 2010-2022
Figure 3.7 Fibrinolytics: Market Forecast ($bn), 2010-2022
Figure 3.8 Vitamin K Antagonists: Market Forecast ($bn), 2010-2022
Figure 3.9 Direct Thrombin Inhibitors: Market Forecast ($bn), 2010-2022
Figure 3.10 Direct Factor Xa Inhibitors: Market Forecast ($bn), 2010-2022
Figure 3.11 Antithrombotic/Anticoagulant Drugs: Therapeutic Class Market Shares (%), 2010, 2012 & 2022
Figure 4.1 Antithrombotic/Anticoagulant Drugs: Market Shares (%) by Country, 2010
Figure 4.2 Antithrombotic/Anticoagulant Drugs: Market Shares (%) by Country, 2012
Figure 4.3 Antithrombotic/Anticoagulant Drugs: Market Shares (%) by Country, 2022
Figure 4.4 US Antithrombotic/Anticoagulant Drug Market Forecast ($bn), 2010-2022
Figure 4.5 Japanese Antithrombotic/Anticoagulant Drug Market Forecast ($bn), 2010-2022
Figure 4.6 Leading European Antithrombotic/Anticoagulant Drug Market Forecasts ($bn), 2010-2022
Figure 4.7 Chinese Antithrombotic/Anticoagulant Drug Market Forecast ($bn), 2010-2022
Figure 4.8 Indian Antithrombotic/Anticoagulant Drug Market Forecast ($bn), 2010-2022
Figure 5.1 Leading Antithrombotic/Anticoagulant Drugs: Sales ($m) and Market Shares (%), 2010
Figure 5.2 Plavix Sales Forecast ($m), 2010-2022
Figure 5.3 Lovenox Sales Forecast ($m), 2010-2022
Figure 5.4 Pletal Sales Forecast ($m), 2010-2022
Figure 5.5 Fragmin Sales Forecast ($m), 2010-2022
Figure 5.6 Asasantin Sales Forecast ($m), 2010-2022
Figure 5.7 Arixtra Sales Forecast ($m), 2010-2022
Figure 5.8 Aspirin Cardio Sales Forecast ($m), 2010-2022
Figure 5.9 Opalmon Sales Forecast ($m), 2010-2022
Figure 5.10 Angiomax Sales Forecast ($m), 2010-2022
Figure 5.11 Activase Sales Forecast ($m), 2010-2022
Figure 5.12 Effient Sales Forecast ($m), 2010-2022
Figure 5.13 Pradaxa Sales Forecast ($m), 2011-2022
Figure 5.14 Brilinta Sales Forecast ($m), 2011-2022
Figure 5.15 Xarelto Sales Forecast ($m), 2011-2022
Figure 6.1 New Antithrombotic Agents
Figure 9.1 Leading Drug Classes: Sales Forecasts ($bn), 2010-2022
Figure 9.2 Leading Drugs: Sales Projections ($m), 2010, 2012 & 2022
Figure 9.3 Leading National Markets: Sales Projections ($bn), 2010, 2012 & 2022
COMPANIES LISTED
Abbott
Ablynx
Acino Pharma
ARCA Discovery
Archemix
Arena Pharmaceuticals
Artisan Pharma
Asahi Kasei Pharma
AstraZeneca
ARYx Therapeutics
Barr Pharmaceuticals
Bayer Healthcare
Berlex
Bharat Biotech
BioInvent
BioVascular
Boehringer Ingelheim
Bristol-Myers Squibb (BMS)
Canyon Pharmaceuticals
Cardiome Pharma
Center for Medicaid and Medicare Services
Daiichi Sankyo
Dainippon Sumitomo
Dr. Reddy's Laboratories
Eisai Pharmaceuticals
Eli Lilly
Endotis Pharma
European Medicines Agency (EMA)
Food and Drug Administration (US FDA)
Genentech
GlaxoSmithKline (GSK)
Janssen
Johnson & Johnson (J&J)
Kowa
Kyowa Hakko
LIMES Institute
Lundbeck
McMaster University
Merck & Co.
Mitsubishi Kasei
Momenta
Myriad Genetics
New Mexico Heart Institute
Novartis
Ono Pharmaceutical
Organon
Otsuka Pharmaceuticals
PAION
Pfizer
Pharmacia
Pharmacyclics
Polymedix
Portola Pharmaceuticals
POZEN
Ranbaxy
Regado Biosciences
Roche
Rovi Pharmaceuticals
Sandoz (part of Novartis)
Sanofi
Speedel
Takeda Pharmaceutical
Talecris Biotherapeutics
Teva Pharmaceuticals
The Medicines Company
The Mount Sinai Medical Center
Trigen Pharma
ThromboGenics
Thrombosis & Atherosclerosis Research Institute, Ontario
Virginia Commonwealth University
Watson Pharmaceuticals
Western Therapeutics Institute
World Health Organization (WHO)
Zena and Michael A. Wiener Cardiovascular Institute, The Mount Sinai Medical Center
Figure 3.1 Antithrombotic/Anticoagulant Drug Market Forecast ($bn), 2010-2022
Figure 3.2 Leading Antithrombotic/Anticoagulant Therapeutic Classes: Market Shares (%), 2010
Figure 3.3 Leading Therapeutic Class Forecast: Market Shares (%), 2012
Figure 3.4 Leading Therapeutic Class Forecast: Market Shares (%), 2022
Figure 3.5 Platelet Aggregation Inhibitors: Market Forecast ($bn), 2010-2022
Figure 3.6 Heparins: Market Forecast ($bn), 2010-2022
Figure 3.7 Fibrinolytics: Market Forecast ($bn), 2010-2022
Figure 3.8 Vitamin K Antagonists: Market Forecast ($bn), 2010-2022
Figure 3.9 Direct Thrombin Inhibitors: Market Forecast ($bn), 2010-2022
Figure 3.10 Direct Factor Xa Inhibitors: Market Forecast ($bn), 2010-2022
Figure 3.11 Antithrombotic/Anticoagulant Drugs: Therapeutic Class Market Shares (%), 2010, 2012 & 2022
Figure 4.1 Antithrombotic/Anticoagulant Drugs: Market Shares (%) by Country, 2010
Figure 4.2 Antithrombotic/Anticoagulant Drugs: Market Shares (%) by Country, 2012
Figure 4.3 Antithrombotic/Anticoagulant Drugs: Market Shares (%) by Country, 2022
Figure 4.4 US Antithrombotic/Anticoagulant Drug Market Forecast ($bn), 2010-2022
Figure 4.5 Japanese Antithrombotic/Anticoagulant Drug Market Forecast ($bn), 2010-2022
Figure 4.6 Leading European Antithrombotic/Anticoagulant Drug Market Forecasts ($bn), 2010-2022
Figure 4.7 Chinese Antithrombotic/Anticoagulant Drug Market Forecast ($bn), 2010-2022
Figure 4.8 Indian Antithrombotic/Anticoagulant Drug Market Forecast ($bn), 2010-2022
Figure 5.1 Leading Antithrombotic/Anticoagulant Drugs: Sales ($m) and Market Shares (%), 2010
Figure 5.2 Plavix Sales Forecast ($m), 2010-2022
Figure 5.3 Lovenox Sales Forecast ($m), 2010-2022
Figure 5.4 Pletal Sales Forecast ($m), 2010-2022
Figure 5.5 Fragmin Sales Forecast ($m), 2010-2022
Figure 5.6 Asasantin Sales Forecast ($m), 2010-2022
Figure 5.7 Arixtra Sales Forecast ($m), 2010-2022
Figure 5.8 Aspirin Cardio Sales Forecast ($m), 2010-2022
Figure 5.9 Opalmon Sales Forecast ($m), 2010-2022
Figure 5.10 Angiomax Sales Forecast ($m), 2010-2022
Figure 5.11 Activase Sales Forecast ($m), 2010-2022
Figure 5.12 Effient Sales Forecast ($m), 2010-2022
Figure 5.13 Pradaxa Sales Forecast ($m), 2011-2022
Figure 5.14 Brilinta Sales Forecast ($m), 2011-2022
Figure 5.15 Xarelto Sales Forecast ($m), 2011-2022
Figure 6.1 New Antithrombotic Agents
Figure 9.1 Leading Drug Classes: Sales Forecasts ($bn), 2010-2022
Figure 9.2 Leading Drugs: Sales Projections ($m), 2010, 2012 & 2022
Figure 9.3 Leading National Markets: Sales Projections ($bn), 2010, 2012 & 2022
COMPANIES LISTED
Abbott
Ablynx
Acino Pharma
ARCA Discovery
Archemix
Arena Pharmaceuticals
Artisan Pharma
Asahi Kasei Pharma
AstraZeneca
ARYx Therapeutics
Barr Pharmaceuticals
Bayer Healthcare
Berlex
Bharat Biotech
BioInvent
BioVascular
Boehringer Ingelheim
Bristol-Myers Squibb (BMS)
Canyon Pharmaceuticals
Cardiome Pharma
Center for Medicaid and Medicare Services
Daiichi Sankyo
Dainippon Sumitomo
Dr. Reddy's Laboratories
Eisai Pharmaceuticals
Eli Lilly
Endotis Pharma
European Medicines Agency (EMA)
Food and Drug Administration (US FDA)
Genentech
GlaxoSmithKline (GSK)
Janssen
Johnson & Johnson (J&J)
Kowa
Kyowa Hakko
LIMES Institute
Lundbeck
McMaster University
Merck & Co.
Mitsubishi Kasei
Momenta
Myriad Genetics
New Mexico Heart Institute
Novartis
Ono Pharmaceutical
Organon
Otsuka Pharmaceuticals
PAION
Pfizer
Pharmacia
Pharmacyclics
Polymedix
Portola Pharmaceuticals
POZEN
Ranbaxy
Regado Biosciences
Roche
Rovi Pharmaceuticals
Sandoz (part of Novartis)
Sanofi
Speedel
Takeda Pharmaceutical
Talecris Biotherapeutics
Teva Pharmaceuticals
The Medicines Company
The Mount Sinai Medical Center
Trigen Pharma
ThromboGenics
Thrombosis & Atherosclerosis Research Institute, Ontario
Virginia Commonwealth University
Watson Pharmaceuticals
Western Therapeutics Institute
World Health Organization (WHO)
Zena and Michael A. Wiener Cardiovascular Institute, The Mount Sinai Medical Center
